SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mangalam Drugs & Organics informs about disclosures

02 Jul 2022 Evaluate

Mangalam Drugs & Organics has informed that the 'Company along with the other appellants' ('Appellants'), have challenged the order dated September 22 2020, passed by the Whole time member ('WTM') of Securities and Exchange Board of India SEBI (SEBI), before Securities Appellate Tribunal ('SAT'). In continuation of that, an order was pronounced by the SAT. In terms of the order passed by the SAT, the impugned order passed by the SEBI against the Company cannot be sustained and hence quashed. The Copy of the SAT order is herewith attached for your reference. The Company is in the process of receiving the Certified Copy of the Order from the Registry.

The above information is a part of company’s filings submitted to BSE.

Mangalam Drugs&Org. Share Price

27.80 -0.45 (-1.59%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×